Zenas BioPharma, Inc. Common Stock
Symbol: ZBIO (NASDAQ)
24.23
▼ (-10.23%) -2.760
Company Description:
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Key Stats
- Today's Open: $27.41
- Today's High: $28.2
- Today's Low: $23.78
- Today's Volume: 441.08K
- Yesterday Close: $26.99
- Yesterday High: $27.13
- Yesterday Low: $25.88
- Yesterday Volume: 519.32K
- Last Min Volume: 7
- Last Min High: $24.23
- Last Min Low: $24.174
- Last Min VWAP: $24.22443
Company Profile
- Name: Zenas BioPharma, Inc. Common Stock
- Website: https://www.zenasbio.com
- Listed Date: 2024-09-13
- Location: WALTHAM, MA
- Market Status: Active
- CIK Number: 0001953926
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.27B
- Round Lot: 100
- Outstanding Shares: 47.11M
- Asset Type: CS
RECENT FILINGS FOR ZBIO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-15 | 3 | View |
| 2025-10-15 | SCHEDULE 13G | View |
| 2025-10-14 | SCHEDULE 13D/A | View |
| 2025-10-14 | SCHEDULE 13D/A | View |
| 2025-10-14 | 4 | View |
| 2025-10-14 | 4 | View |
| 2025-10-14 | SCHEDULE 13D/A | View |
| 2025-10-14 | 4 | View |
| 2025-10-09 | 4 | View |
| 2025-10-09 | SCHEDULE 13D/A | View |
| 2025-10-09 | 4 | View |
| 2025-10-09 | 4 | View |
| 2025-10-08 | S-3ASR | View |
| 2025-10-08 | 8-K | View |
| 2025-09-08 | SCHEDULE 13G/A | View |
| 2025-09-02 | 8-K | View |
| 2025-08-12 | S-8 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-06 | SCHEDULE 13G/A | View |
Latest News on ZBIO